Form 4: ORIC CFO Granted Stock Options, RSUs

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, was granted 206,500 stock options and 34,500 restricted stock units.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), received equity compensation on January 2, 2026.
• Piscitelli was granted 206,500 stock options with an exercise price of $8.17 per share, which expire on January 1, 2036.
• The stock options vest 25% on January 2, 2027, with the remaining shares vesting monthly at a rate of 1/36th thereafter.
• Additionally, Piscitelli received 34,500 Restricted Stock Units (RSUs) on January 2, 2026.
• Each RSU represents a contingent right to receive one share of ORIC Common Stock.
• The RSUs vest in three equal installments of 1/3rd on December 15, 2026, December 15, 2027, and December 15, 2028.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a key executive, which is generally viewed positively as it aligns management's interests with shareholders. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• Grant of significant equity compensation to the Chief Financial Officer, Dominic Piscitelli, totaling 206,500 stock options and 34,500 Restricted Stock Units.
• Equity grants align the interests of the CFO with those of shareholders, incentivizing long-term company performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, compliant transaction.

Negatives

• No direct negative information is presented in this Form 4 filing, which primarily discloses an equity grant.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

Not applicable. This filing does not provide forward-looking statements or guidance.

Industry Context

Equity compensation, including stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. These grants are designed to align executive interests with long-term shareholder value creation, a common strategy among companies like Oric Pharmaceuticals.

Comparison to Industry Standards

• The structure of equity grants, involving both stock options and restricted stock units with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology sector.
• Similar compensation structures are common at peer companies such as Relay Therapeutics (RLAY) or Revolution Medicines (RVMD), where executives receive a mix of time-based and performance-based equity to foster long-term commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief Financial Officer's long-term financial interests with those of the shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs, potentially impacting morale and retention.

Next Steps

• Vesting of stock options according to the schedule: 25% on January 2, 2027, then 1/36th of the remaining shares monthly thereafter.
• Vesting of Restricted Stock Units according to the schedule: 1/3rd on December 15, 2026, December 15, 2027, and December 15, 2028.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Form 4, SEC filing, stock options, restricted stock units, equity compensation, insider transaction, Dominic Piscitelli, CFO, Rule 10b5-1